<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807127</url>
  </required_header>
  <id_info>
    <org_study_id>S63357</org_study_id>
    <nct_id>NCT04807127</nct_id>
  </id_info>
  <brief_title>A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade</brief_title>
  <official_title>A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this prospective non-interventional exploratory monocentric study is to&#xD;
      characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer&#xD;
      patients experiencing cancer therapy-induced pneumonitis on a single-cell scale. These&#xD;
      mechanistic insights can directly lead to putative diagnostic biomarkers and therapeutic&#xD;
      targets.&#xD;
&#xD;
      A second highly clinically relevant hypothesis is that single-cell profiling of blood samples&#xD;
      will reveal circulating biomarkers of ICB toxicity, making non-invasive diagnosis feasible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will apply single cell RNA- and TCR-sequencing on up to 5,000 single cells&#xD;
      per sample. Additionally, cell surface protein expression can be integrated with the&#xD;
      transcriptional information. Various bioinformatics pipelines, including Seurat, will be used&#xD;
      to identify different cell clusters, which through marker gene expression will be assigned to&#xD;
      known cell types, cellular subtypes or phenotypes. For instance, this will make it possible&#xD;
      to monitor the abundance of PD-1/PD-L1 expressing T-cells, cytotoxic T-cells,&#xD;
      immune-suppressive myeloid cells etc. The following parameters at single-cell level will be&#xD;
      relevant, amongst others:&#xD;
&#xD;
        -  The composition and relative abundancies of established immune cell types (e.g. T cells&#xD;
           (CD4+, CD8+ and regulatory subsets), NK cells, B cells, MDSCs, macrophages, neutrophils,&#xD;
           dendritic cells). Transcriptomic data for each of these immune cell subtypes will be&#xD;
           analyzed, allowing characterization of specific gene expression programs that define&#xD;
           specific phenotypic states.&#xD;
&#xD;
        -  Composition of all stromal cellular subtypes identified by single-cell transcriptomics.&#xD;
&#xD;
        -  A gene regulatory network for each cell type and cellular subtype (or cell state) will&#xD;
           be established and master transcriptional regulators will be identified. Individual&#xD;
           T-cells and T-cell subclusters will be classified based on interferon activation, high&#xD;
           rates of proliferation and transcription and increased granzyme expression, which are&#xD;
           all indicative of T-cell activation.&#xD;
&#xD;
      Blood samples will be subjected to similar single-cell experimental procedures. First,&#xD;
      peripheral blood mononuclear cells (PBMC) are isolated using Ficoll density gradient&#xD;
      centrifugation. Single-cell transcriptome analysis in combination with CITE-seq will be&#xD;
      performed on 5000 PBMC. Cellular composition will be determined using the same bioinformatic&#xD;
      pipelines as used for processing the BAL fluid cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune cell proportions, as determined by scRNA-seq, present in ICI-/RT-/TKI-induced pneumonitis BAL fluid</measure>
    <time_frame>From date of inclusion until study completion, on average 2 years</time_frame>
    <description>By identifying and statistically comparing the percentages of immune cell subtypes present in ICI-/RT-/TKI-induced pneumonitis BAL fluid, we aim to i) understand which immune processes drive these adverse events ii) identify putative molecular biomarkers iii) identify putative therapeutic targets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differentially expressed genes in BAL fluid, as determined by scRNA-seq, discriminating ICI-/RT-/TKI-induced pneumonitis</measure>
    <time_frame>From date of inclusion until study completion, on average 2 years</time_frame>
    <description>By identifying differentially expressed genes in ICI- vs. RT- vs. TKI-induced pneumonitis BAL fluid, we aim to i) understand which immune processes drive these adverse events ii) identify putative molecular biomarkers iii) identify putative therapeutic targets</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune cell proportions, as determined by scRNA-seq, present in ICI-/RT-/TKI-induced pneumonitis peripheral blood mononuclear cells</measure>
    <time_frame>From date of inclusion until study completion, on average 2 years</time_frame>
    <description>By identifying and statistically comparing the percentages of immune cell subtypes present in ICI-/RT-/TKI-induced pneumonitis peripheral blood mononuclear cells, we aim to i) understand which immune processes drive these adverse events ii) identify putative molecular biomarkers iii) identify putative therapeutic targets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differentially expressed genes in PBMC, as determined by scRNA-seq, discriminating ICI-/RT-/TKI-induced pneumonitis</measure>
    <time_frame>From date of inclusion until study completion, on average 2 years</time_frame>
    <description>By identifying differentially expressed genes in ICI- vs. RT- vs. TKI-induced pneumonitis PBMC, we aim to i) understand which immune processes drive these adverse events ii) identify putative molecular biomarkers iii) identify putative therapeutic targets</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pneumonitis, Interstitial</condition>
  <condition>Immunotherapy</condition>
  <condition>Immune-related Adverse Events</condition>
  <arm_group>
    <arm_group_label>ICI-pneumonitis</arm_group_label>
    <description>Cancer patients experiencing ICI-pneumonitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy induced pneumonitis</arm_group_label>
    <description>Cancer patients experiencing RT-pneumonitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI-induced pneumonitis</arm_group_label>
    <description>Cancer patients experiencing TKI-induced pneumonitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune checkpoint blockade</intervention_name>
    <description>ICI, administered as standard-of-care treatment</description>
    <arm_group_label>ICI-pneumonitis</arm_group_label>
    <other_name>Pembrolizumab</other_name>
    <other_name>Durvalumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted therapy</intervention_name>
    <description>TKI, administered as standard-of-care treatment</description>
    <arm_group_label>TKI-induced pneumonitis</arm_group_label>
    <other_name>TKI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>RT, administered as standard-of-care treatment</description>
    <arm_group_label>Radiotherapy induced pneumonitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  BAL samples will not be retained&#xD;
&#xD;
        -  PBMC samples will be stored at -80°C, for batch processing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients experiencing cancer-treatment induced pneumonitis, undergoing bronchoscopy with&#xD;
        BAL&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult M/F/X (&gt;= 18 years)&#xD;
&#xD;
          -  Patients receiving or having received treatment per guidelines&#xD;
&#xD;
          -  Patients undergoing bronchoscopy with BAL, for possible cancer treatment-induced&#xD;
             pneumonitis&#xD;
&#xD;
          -  Not included in other clinical trials&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • Collected material not suitable for further processing in this study (e.g. bad quality).&#xD;
        This decision will be made in consultation with a lab technician and/or bio-informatician,&#xD;
        specialized in single-cell analysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Els Wauters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals - KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Els Wauters, MD, PhD</last_name>
    <phone>+3216340942</phone>
    <email>els.wauters@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Els Wauters, MD, PhD</last_name>
      <phone>016340942</phone>
      <email>els.wauters@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

